Prevention of metastasis by an ultra-short acting and the most selective beta1 blocker, Landiolol

Phase 2

• Conditions: non-small cell lung cancer; D002289

• Registration Number: JPRN-jRCT2011180004
• Lead Sponsor: Hida Yasuhiro

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-01-17
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

1.NSCLC is suspected.
2.Radiologically diagnosed invasive lung tumor (cT1a or more in UICC 8th edition)
3.Lobectomy, bi-lobectomy or pneumonectomy is intended
4.Mediastinal lymph node dissection ND2a-1 or more is intended
5.No history of cancer (carcinoma in situ is excluded) treatment within 5 years.
6.Performance Status(PS)0 or 1

Exclusion Criteria

1.Malignant tumors within 5years
2.Mental disorders
3.Patients on beta agonists or antagonists
4.Preoperative treatments for NSCLC
5.Active infections
6.Contraindication to use ONO-1011

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Relapse-free survival [Time Frame: 2 years]<br>Over all survival [Time Frame: Through study completion, an average of 3 years]

Secondary Outcome Measures

Name	Time	Method
1)Efficacy/<br>Evaluation of treatments after relapse [Time Frame: Up to 4 years and 5 months]<br>2)Safety/<br>Evaluation of adverse event, blood pressure, 12-lead electrocardiography, clinical laboratory test [Time Frame: Up to 7 days after surgery]<br>Evaluation of incidence of perioperative complication [Time Frame: Up to 30 days after surgery]